English

AlzeCure publishes its Year-end Report for 2019

Report this content

February 28, 2020 

AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its Year-end Report for 2019 is now available on the company’s website: https://www.alzecurepharma.se/sv/section/investerare/finansiella-rapporter/

Financial information for October - December 2019

  • Net sales during the period totaled SEK 0 thousand (0).
  • Earnings for the period totaled SEK –15,635 thousand (–12,967).
  • Earnings per share, basic, totaled SEK –0.41 (–0.42).
  • Total assets at the end of the period amounted to SEK 186,755 thousand (237,782).
  • Cash and cash equivalents at the end of the period totaled SEK 182,499 thousand (234,549).

Financial information for January - December 2019

  • Net sales during the period totaled SEK 0 thousand (0).
  • Earnings for the period totaled SEK –50,858 thousand (–35,985).
  • Earnings per share, basic, totaled SEK –1.35 (–1.58).
  • Total assets at the end of the period amounted to SEK 186,755 thousand (237,782).
  • Cash and cash equivalents at the end of the period totaled SEK 182,499 thousand (234,549).
  • The Board proposes that no dividend be paid for the financial year.

Significant events January - December 2019

  • In March the company initiated a new drug project in the field of pain, TrkA-NAM.
  • The company was represented at the International Conference on Alzheimer’s & Parkinson’s Diseases where it gave two presentations.
  • In May the company chose to redirect the drug candidate ACD855 from cognitive dysfunction to an ocular indication and ACD856 became the primary drug candidate for cognitive dysfunction instead.
  • At the annual general meeting on May 22, the company resolved to issue a warrant program aimed at the company’s Board of Directors.
  • In December the company obtained the necessary approvals from the regulatory authorities to initiate the first clinical study for the drug candidate ACD856 within the NeuroRestore platform. The company initiated the study shortly thereafter.
     

Significant events after the end of the period

  • In January, the company in-licensed a new project, VR1, which focuses on neuropathic pain and is in the clinical development phase.
  • Martin Jönsson was appointed to serve as the new Chief Executive Officer on January 8, 2020. Martin has worked in the global pharmaceutical industry for more than 20 years, with extensive experience from various executive positions at both Ferring Pharmaceutical and Roche.

Read the full report  at: https://www.alzecurepharma.se/sv/section/investerare/finansiella-rapporter/

The information was submitted for publication, through the agency of the contact person set out below at 08.00 am CET on February 28, 2020.  

For more information, please contact

Martin Jönsson, CEO

Tel: +46 (0)70-786 94 43

E-mail: martin.jonsson@alzecurepharma.com

About AlzeCure Pharma

AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in innovative drug research with a primary focus on Alzheimer’s disease and pain. The company is listed on Nasdaq First North Premier Growth Market and is developing five drug candidates based on the two research platforms, NeuroRestore® and Alzstatin®. The NeuroRestore platform comprises symptom-relieving drug candidates while Alzstatin comprises disease modifying and preventive drug candidates. A diversified portfolio of drug candidates that act on central signaling pathways in the brain also opens up for other indications such as cognitive dysfunctions in traumatic brain injury (TBI), sleep apnea and Parkinson’s disease. The company also has two projects in the field of pain, TrkA-NAM and VR1. FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se, is the company’s certified adviser. For further information, please visit our website at www.alzecurepharma.se

Subscribe

Documents & Links